Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.

Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.

Item
http://www.wikidata.org/entity/Q42445553
Function, regulation and pathological roles of the Gab/DOS docking proteinsFunctional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signalingPaternal age effect mutations and selfish spermatogonial selection: causes and consequences for human diseaseARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumorsDeletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?Costello Syndrome and Umbilical Ligament Rhabdomyosarcoma in Two Pediatric Patients: Case Reports and Review of the Literature.The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms.Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.Behavioral phenotype in Costello syndrome with atypical mutation: a case report.A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development.An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.RIT1 controls actin dynamics via complex formation with RAC1/CDC42 and PAK1.Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C
P2860

Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.

Item
http://www.wikidata.org/entity/Q42445553
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Oncogenic HRAS mutations cause ...... tients with Costello syndrome.
@en
Oncogenic HRAS mutations cause ...... tients with Costello syndrome.
@nl
type
label
Oncogenic HRAS mutations cause ...... tients with Costello syndrome.
@en
Oncogenic HRAS mutations cause ...... tients with Costello syndrome.
@nl
prefLabel
Oncogenic HRAS mutations cause ...... tients with Costello syndrome.
@en
Oncogenic HRAS mutations cause ...... tients with Costello syndrome.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Oncogenic HRAS mutations cause ...... tients with Costello syndrome.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698